Recombinant Human Ephrin type-B receptor 6 (EPHB6), partial

Code CSB-YP007733HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP007733HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP007733HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP007733HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP007733HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
EPHB6
Uniprot No.
Alternative Names
EPH receptor B6; Ephb6; EPHB6_HUMAN; Ephrin type B receptor 6 precursor; Ephrin type-B receptor 6; HEP; MGC129910; MGC129911; Tyrosine protein kinase defective receptor EPH 6; Tyrosine-protein kinase-defective receptor EPH-6
Species
Homo sapiens (Human)
Protein Length
Partial
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Kinase-defective receptor for members of the ephrin-B family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2.
Gene References into Functions
  1. using an EphB6 mouse knockout model we found that the loss of EphB6 does not initiate intestinal tumorigenesis and is not involved in the early tumor progression through the adenoma-to-carcinoma transition. PMID: 28262839
  2. Data indicate that EphB6 protein was decreased in gastric carcinoma compared with normal mucosa. Analytic results based on pathological parameters suggests that EphB6 protein may inhibit metastasis of gastric carcinoma. PMID: 28453458
  3. Authors provide evidence that an intrinsically kinase-inactive member of the Eph group of receptor tyrosine kinases, EPHB6, induces marked fragmentation of the mitochondrial network in breast cancer cells of triple-negative origin, lacking expression of the estrogen, progesterone and HER2 receptors. PMID: 27788485
  4. SRC kinase is a synthetic lethality partner of EPHB6 in triple-negative breast cancer cells PMID: 27418135
  5. Study is the first to demonstrate that EphB6 overexpression together with Apc gene mutations may enhance proliferation, invasion and metastasis by colorectal epithelial cells. PMID: 27145271
  6. Melanomas from geographically different regions in New Zealand have markedly different mutation frequencies, in particular in the NRAS and EPHB6 genes, when compared to The Cancer Genome Atlas database or other populations. These data have implications for the causation and treatment of malignant melanoma in New Zealand. PMID: 27191502
  7. Low EPHB6 expression is associated with prostate cancer metastasis. PMID: 28826721
  8. Enhanced EphB6 expression was significantly associated with Thyroid Lesions. PMID: 26220827
  9. EphB6 protein may be used as a new marker for prognosis for tongue squamous cell carcinoma. PMID: 26617870
  10. EphB6 is a new biomarker for distinguishing high- and low-grade ovarian serous carcinoma, and may be a potential prognostic marker in ovarian serous carcinomas. PMID: 26468391
  11. EphB6 also interacts with the Hsp90 chaperone. PMID: 25152371
  12. We demonstrate that EphB6 reexpression forces metastatic melanoma cells to deviate from the canonical migration pattern observed in the chick embryo transplant model PMID: 24836890
  13. Results suggest that erythropoietin-producing hepatocyte (Eph) receptor B6 (EphB6) may represent a useful tissue biomarker for the prediction of survival rate in colorectal cancers (CRCs). PMID: 24912672
  14. Studies clearly demonstrate an inverse relationship between the levels of phospho-ERK and the abundance of cadherin 17, beta-catenin and phospho-GSK3beta in EPHB6-expressing MDA-MB-231 cells. PMID: 25331796
  15. The alterations in miRNAs and their target mRNAs also suggest indirect involvement of EphB6 in PI3K/Akt/mTOR pathways. PMID: 21811619
  16. results indicate that tumor invasiveness-suppressing activity of EPHB6 is mediated by its ability to sequester other kinase-sufficient and oncogenic EPH receptors PMID: 21737611
  17. Nonsynonymous variants of EPHB6 is associated with familial colorectal cancer. PMID: 21351276
  18. expression of more than 70 proteins was altered in EphB6-transfected MDA-MB-231 cells; proteins are involved in glycolysis, cell cycle regulation, tumor suppression, cell proliferation, mitochondrial metabolism, mRNA splicing, DNA replication and repair PMID: 20952760
  19. The loss of EPHB6 expression in more aggressive breast carcinoma cell lines is regulated in a methylation-dependent manner. The EPHB6 methylation-specific PCR has clinical implications for the prognosis and/or diagnosis of breast and other cancer types PMID: 20181626
  20. Findings suggest a new role for EphB6 in suppressing cancer invasiveness and cell attachment through c-Cbl-dependent signaling. PMID: 20086179
  21. interaction between EphB6 and its ligands facilitates T cell responses to antigen PMID: 12393850
  22. EphB6 may play an important role in regulating thymocyte differentiation and modulating responses of mature T cells. PMID: 12517763
  23. lower EphB6 expression has a role in melanoma progression to metastatic disease PMID: 14612926
  24. EphB6 can both positively and negatively regulate cell adhesion and migration PMID: 15955811
  25. The potential significance of EphB6 to serve as a diagnostic and prognostic indicator is discussed. PMID: 16364251
  26. the two peptides derived from EphB6v might be appropriate targets for peptide-based specific immunotherapy for HLA-A2(+) patients with various cancers PMID: 18754880
  27. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. PMID: 19234485
  28. The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. PMID: 19513565
  29. Cross-linking of EphB6 alters profiles of lymphokine secretion, inhibits proliferation, induces Fas-mediated apoptosis of Jurkat leukemic T cells, and transduces signals into the cells via proteins it associates with. PMID: 11466354

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted.
Protein Families
Protein kinase superfamily, Tyr protein kinase family, Ephrin receptor subfamily
Tissue Specificity
Expressed in brain. Expressed in non invasive breast carcinoma cell lines (at protein level). Strong expression in brain and pancreas, and weak expression in other tissues, such as heart, placenta, lung, liver, skeletal muscle and kidney. Expressed in bre
Database Links

HGNC: 3396

OMIM: 602757

KEGG: hsa:2051

STRING: 9606.ENSP00000376684

UniGene: Hs.380089

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1